Browsing Tag
Hypercon
1 post
Halozyme Therapeutics (HALO) completes $900m Elektrofi deal—what’s next for its royalty roadmap?
Halozyme finalizes $900M Elektrofi deal to strengthen its subcutaneous biologics platform. Discover how this move impacts future royalties and delivery formats.